v3.26.1
Segment, Geographic and Other Revenue Information - Schedule of Significant Biopharma Segment Expenses (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 28, 2026
Jun. 29, 2025
Jun. 28, 2026
Jun. 29, 2025
Segment Reporting [Line Items]        
Revenues: $ 15,034 $ 14,653 $ 29,484 $ 28,367
Cost of sales [1] 4,092 3,778 7,640 6,624
Selling, informational and administrative expenses [1] 3,411 3,415 6,372 6,446
Research and development expenses [1] 2,809 2,482 5,299 4,685
Acquired in-process research and development expenses 16 2 153 11
Other (income)/deductions––net 3,716 739 4,577 1,692
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss) [2] (653) 3,044 2,517 5,828
Biopharma [Member]        
Segment Reporting [Line Items]        
Revenues: [3] 14,661 14,305 28,822 27,746
Cost of sales 3,188 3,075 6,222 5,389
Selling, informational and administrative expenses 2,344 2,343 4,475 4,529
Research and development expenses 2,376 2,109 4,513 4,050
Acquired in-process research and development expenses 16 2 153 11
Other (income)/deductions––net (151) (115) (267) (193)
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss) $ 6,887 $ 6,891 $ 13,725 $ 13,960
[1] Exclusive of amortization of intangible assets.
[2] Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss). Effective in the third quarter of 2025, certain expenses for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified Selling, informational and administrative expenses of approximately $38 million in the second quarter of 2025 and $74 million in the first six months of 2025 from Other business activities to Biopharma to conform to the current period presentation.
[3] In the first quarter of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within our Biopharma reportable segment. See Note 13A above. We reclassified prior period amounts to conform to the current period presentation